Business
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately 53,000 total prescriptions were filled for Emrosi™ during FY2025 Payer access for Emrosi™ available to over 100 million U.S. commercial lives Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 25, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM)
About this update from Fortress Biotech, Inc.
[{"type":"image","alt":"Journey Medical Corporation","displaySize":"","headline":null,"caption":"Journey Medical Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":210,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/e9d5afac46b9f27fa4ee4033197e08d3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/neErxfmHzpck8XzIhTCP2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4Mg--/https://media.zenfs.com/en/globenewswire.com/e9d5afac46b9f27fa4ee4033197e08d3","width":210,"height":91}},"lazy":false},{"type":"text","content":"Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024","length":79,"tagName":"p"},{"type":"text","content":"Emrosi™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025","length":117,"tagName":"p"},{"type":"text","content":"Approximately 53,000 total prescriptions were filled for Emrosi™ during FY2025","length":83,"tagName":"p"},{"type":"text","content":"Payer access for Emrosi™ available to over 100 million U.S. commercial lives","length":91,"tagName":"p"},{"type":"text","content":"Company to hold conference call today at 4:30 p.m. ET ","length":53,"tagName":"p"},{"type":"text","content":"SCOTTSDALE, Ariz., March 25, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2025.","length":441,"tagName":"p"},{"type":"text","content":"Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer, said, “We delivered a year of meaningful commercial progress, highlighted by the successful launch and rapid uptake of Emrosi™, which is driving solid revenue growth and expanding our presence in medical dermatology. Our financial performance continues to strengthen with rising net product revenues, improving gross margins and expense optimization, supported by disciplined investment in our dermatology focused sales infrastructure. Emrosi™ achieved strong prescription momentum and broader payer access throughout the year, and its differentiated c...